Diversify Advisory Services LLC Buys 3,394 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Diversify Advisory Services increased its Krystal Biotech stake by 247.2% in the third quarter, purchasing 3,394 additional shares and ending with a position valued at approximately $1.57 million. Institutional investors collectively own 86.29% of the company.
• Wall Street remains broadly bullish on KRYS, with a consensus “Buy” rating and an average price target of $377.20. Two analysts rate the stock a Strong Buy, while ten rate it Buy and two assign a Hold rating.
• Krystal Biotech shares opened at $311.50, down 2.7%, while the company reported quarterly EPS of $1.79, exceeding estimates of $1.70. Two insiders sold 25,000 shares each, though insiders still own 13.10% of the stock.

Diversify Advisory Services LLC boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 247.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,767 shares of the company's stock after buying an additional 3,394 shares during the period. Diversify Advisory Services LLC's holdings in Krystal Biotech were worth $1,573,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech in the second quarter valued at $30,000. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth about $34,000. USA Financial Formulas purchased a new position in shares of Krystal Biotech during the 1st quarter worth about $44,000. Integrated Wealth Concepts LLC purchased a new position in shares of Krystal Biotech during the 2nd quarter worth about $46,000. Finally, GK Wealth Management LLC bought a new position in Krystal Biotech during the 3rd quarter valued at about $59,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KRYS. Jefferies Financial Group reissued a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Chardan Capital upgraded Krystal Biotech to a "strong-buy" rating in a research report on Monday, August 3rd. William Blair raised Krystal Biotech to a "strong-buy" rating in a research note on Wednesday, September 23rd. Royal Bank Of Canada assumed coverage on Krystal Biotech in a report on Friday, August 14th. They issued an "outperform" rating and a $400.00 price target on the stock. Finally, Weiss Ratings cut Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $377.20.

Insider Buying and Selling at Krystal Biotech

In other news, Director Dino Rossi sold 25,000 shares of the business's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company's stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company's stock.

Krystal Biotech Stock Down 2.7%

Shares of NASDAQ:KRYS opened at $311.50 on Friday. The company has a market capitalization of $9.22 billion, a price-to-earnings ratio of 39.04 and a beta of 0.50. Krystal Biotech, Inc. has a 52 week low of $183.26 and a 52 week high of $382.54. The firm has a 50 day moving average of $339.36 and a 200 day moving average of $325.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 7.33 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.